|Bid||0.09 x 1000|
|Ask||0.09 x 1400|
|Day's Range||0.0765 - 0.1182|
|52 Week Range||0.0765 - 2.8000|
|Beta (3Y Monthly)||3.38|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.00|
During a hearing Thursday at the U.S. Bankruptcy Court in New York, Judge James Garrity Jr. expressed concern about moving too quickly but authorized the company to continue to pay employees, access bank accounts and maintain other routine operations. Inc., formerly known as Valeant Pharmaceuticals International Inc., for around $200 million in cash.
NEW YORK, NY / ACCESSWIRE / December 13, 2018 / Shares of both Neurocrine Biosciences and Synergy Pharmaceuticals were in the red on Wednesday after announcing discouraging developments. Synergy is selling its business assets while Neurocrine Biosciences failed to meet a primary goal in a mid-stage trial. Neurocrine Biosciences, Inc. shares were down almost 14% on about 13 million shares traded yesterday.
Synergy Pharmaceuticals Inc. filed for bankruptcy Wednesday with a plan to sell its assets to Bausch Health Companies Inc. for around $200 million in cash. The deal includes all rights to Synergy’s flagship product Trulance, a tablet approved for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation, as well as another development-stage compound and related intellectual property. “We have worked diligently to serve our patients, health care professionals and other stakeholders by bringing Trulance to market and developing other [gastrointestinal] therapies to address previously unmet needs,” said Synergy Chief Executive Troy Hamilton.
Synergy Pharmaceuticals (NASDAQ:SGYP) has filed for Chapter 11 bankruptcy in a voluntary petition with another pharmaceutical company absorbing most of the company’s assets once the move goes through. The bankruptcy filing will be followed by Bausch Health (NYSE:BHC) taking over as a “stalking horse” bidder for the company in an auction and sale process that has been approved by a court. The acquisition of Synergy’s assets will be part of a deal valued at roughly $200 million that is slated to be complete at the end of the first quarter of 2019.
The problem doesn’t appear to have been the stigma around talking about bowel movements — an issue Synergy hoped to address with those (animated!) emojis — but rather a highly competitive market.(2)Trulance has made little headway against better established drugs like Allergan PLC’s Linzess and Takeda Pharmaceutical Co.’s Amitiza.
, formerly known as Valeant Pharmaceuticals, is back in the acquisitions game after a long hiatus. The deal gives Bausch access to Synergy’s lead drug Trulance, which treats irritable bowel syndrome. The deal is Bausch’s first major acquisition since 2015.
Synergy Pharmaceuticals Inc. shares slid 55% in premarket trade Wednesday, after the company filed a voluntary petition for Chapter 11, allowing Bausch Health Cos. Inc. to serve as "stalking horse" bidder for the company in a court-approved auction and sale processes. Bausch, the former Valeant, will acquire Synergy's assets in a deal valued at about $200 million that is expected to close in the first quarter of 2019. Synergy specializes in gastrointestinal therapies, including its flagship Trulance product, a once-a-day table approved for adults with chronic constapion and irritable bowel syndrome with constipation. That product will complement Bausch's Salix business, Chief Executive Joseph Papa said in a statement. Bausch shares were up slightly premarket, and have gained 11% in 2018, while the S&P 500 has fallen 1.4%.
LAVAL, Quebec, Dec. 12, 2018 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has entered into a definitive agreement to acquire certain assets of Synergy Pharmaceuticals Inc. (SGYP) ("Synergy") in a transaction valued at approximately $200 million plus certain assumed liabilities. Synergy filed a voluntary petition for reorganization under Chapter 11 of the U.S. Code (the "Bankruptcy Code") with the U.S. Bankruptcy Court for the Southern District of New York (the "Bankruptcy Court") earlier today. Under the terms of the agreement, and subject to Bankruptcy Court approval, Bausch Health will serve as the "stalking horse" bidder in a court-supervised auction and sale process, which Synergy will conduct pursuant to Section 363 of the Bankruptcy Code.
NEW YORK, Dec. 12, 2018 /PRNewswire/ -- Synergy Pharmaceuticals Inc. (SGYP) (the "Company" or "Synergy"), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced an agreement with Bausch Health Companies Inc., through which Bausch Health would acquire substantially all of Synergy's assets, including all rights to TRULANCE® (plecanatide), dolcanatide and related intellectual property, for approximately $200 million in cash, subject to certain adjustments at closing, plus the assumption of certain liabilities related to the assets to be acquired. The sale is subject to a competitive process and the Company's receipt of higher and better offers.
NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Synergy Pharma (SGYP) delivered earnings and revenue surprises of -7.69% and -29.04%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the New York-based company said it had a loss of 14 cents. The biopharmaceutical company posted revenue of $11.1 million in the period. In the final minutes of trading on Thursday, ...
Synergy Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal therapies, today reported its financial results and business update for the three months ended September 30, 2018.
The revelation that this biotech may be on borrowed time is a great reminder to investors to analyze balance sheets.
Synergy Pharmaceuticals Inc. (SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that Melvin K. Spigelman, M.D., who has served as an Independent Director of Synergy since August 2008, will now assume the role of Chairman of the Board, effective immediately. Synergy’s outgoing Executive Chairman, Gary S. Jacob, Ph.D., will leave the Company to pursue other opportunities. Synergy is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies.
The markets are in the red again on Friday as all three major indexes are down by over 1%. Among the stocks trending include Synergy Pharmaceuticals Inc (NASDAQ:SGYP), Tesla Inc (NASDAQ:TSLA),Tencent Holdings Ltd (OTCMKTS:TCTZF),Flex Ltd (NASDAQ:FLEX), Lantronix Inc (NASDAQ:LTRX). Let’s take a closer look at why investors have been watching or selling those stocks. For those of you interested in […]
shareholders have quite a mess on their hands. “To date, the offers received to acquire Synergy have been significantly below the company’s current market value, and it has been unable to consummate any partnerships,” the company said in a statement.
Shares collapse after management provides investors with a series of troubling business updates. Here's the must-know information for shareholders.
Synergy Pharmaceuticals Inc. (SGYP) (the “Company” or “Synergy”), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today provided a business update. In April 2015, prior to the FDA approval and launch of TRULANCE® (plecanatide) in 2017, Synergy hired a top tier advisory firm to engage external parties and evaluate all strategic options available to the Company, including US and ex-US partnerships and a possible sale of the Company. Ultimately, there were no offers to acquire the Company and no partnership opportunities emerged in this evaluation that it believed aligned with the Company strategically or financially.
Synergy Pharmaceuticals Inc. (SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that the company will present new analyses that further reinforce the efficacy and safety of TRULANCE® (plecanatide) for adult patients with chronic idiopathic constipation (CIC) or irritable bowel syndrome with constipation (IBS-C), specifically in patients aged 65 and older and in patients using concomitant acid suppression medications such as proton pump inhibitors (PPIs) and/or histamine receptor antagonists (H2 blockers).
Investors need to pay close attention to Synergy Pharmaceuticals (SGYP) stock based on the movements in the options market lately.